Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1382_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
11 Мб
Скачать
☆
120
ENDOCRINE SURGERY
58. Demidchik YE, Saenko VA, Yamashita S. Childhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at present. Arq Bras Endocrinol Metabol. 2007; 51(5):748–62.
59. Nikiforov YE, Gnepp DR. Pathomorphology of thyroid gland lesions associated with radiation exposure: the Chernobyl experience and review of the literature. Adv Anat Pathol. 1999; 6(2):78–91.
60. Williams ED, Abrosimov A, Bogdanova T, et al. Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br J Cancer. 2004; 90(11):2219–24.
61. Bogdanova TI, Zurnadzhy LY, Greenebaum E, et al. A cohort study of thyroid cancer and other thyroid dis­eases after the Chornobylaccident: pathology analysisof thyroid cancer cases in Ukraine detected during the first screening (1998–2000). Cancer. 2006; 107(11):2559–66.
62. Ito T, Seyama T, Iwamoto KS, et al. Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet. 1994; 344(8917):259.
63. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Cher­nobyl nuclear accident. Cancer Res. 1995; 55(23): 5617–20.
64. Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphologi­cal variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57(9):1690–4.
65. Smida J, Salassidis K, Hieber L, et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer. 1999; 80(1):32–8.
66. Thomas GA, Bunnell H, CookHA, et al.High prevalenceof RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab. 1999; 84(11):4232–8.
67. Bongarzone I, Vigneri P, Mariani L, et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 1998; 4(1):223–8.
68. Learoyd DL, Messina M, Zedenius J, et al. RET/PTC and RET tyrosine kinase expression in adult papillary thyr­oid carcinomas. J Clin Endocrinol Metab. 1998; 83(10): 3631–5.
69. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinol­ogy. 2007; 148(3):936–41.
70. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001; 8(6):345–54.
71. Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: bio­logical, phenotypic, and clinical implications. Clin Can­cer Res. 2000; 6(3):1093–103.
72. Robbins J, Dunn JT, Bouville A, et al. Iodine nutrition and the risk from radioactive iodine: a workshop report in the chernobyl long-term follow-up study. Thyroid. 2001; 11(5):487–91.
73. Mityukova TA, AstakhovaLN, Asenchyk LD, et al. Urin­ary iodine excretion in Belarus children. Eur J Endocri­nol. 1995; 133(2):216–7.
74. Ashizawa K, Shibata Y, Yamashita S, et al. Prevalence of goiter and urinary iodine excretion levels in children around Chernobyl. J Clin Endocrinol Metab. 1997; 82(10):3430–3.
75. Tronko M, Kravchenko V, Fink D, etal. Iodineexcretion in regions of Ukraine affected by the Chornobyl Acci­dent: experience of the Ukrainian-American cohort study of thyroid cancer and other thyroid diseases. Thyroid. 2005; 15(11):1291–7.
76. Shakhtarin VV, Tsyb AF, Stepanenko VF, et al. Iodine deficiency, radiation dose, and the risk ofthyroid cancer among children and adolescents in the Bryansk region of Russia following the Chernobyl power station acci­dent. Int J Epidemiol. 2003; 32(4):584–91.
9

Poorly Differentiated and Undifferentiated Thyroid Cancer

Anthony J. Chambers and Janice L. Pasieka
Introduction
Thyroid carcinoma in its differentiated form is associated with an excellent long-term prog­nosis, with surgical resection and the use of radioactive iodine providing effective treatment and cure in a high proportion of patients. In contrast to well-differentiated thyroid cancer (WDTC), poorly differentiated forms of thyroid cancer exist which are associated with a more aggressive clinical course and a correspond­ingly less favorable prognosis. At the extreme of the spectrum of differentiation of thyroid cancers, undifferentiated (anaplastic) thyroid cancer (UTC) is one of the most biologically aggressive and lethal of human malignancies, displaying rapid invasive growth and early metastatic dissemination. It is recognized that some thyroid cancers display a degree of dif­ferentiation and biological behavior which is intermediate between WDTC and UTC in this spectrum, and this group has been referred to as poorly differentiated thyroid cancer (PDTC).
Poorly Differentiated Thyroid Cancer
In contrast to more differentiated forms of thyr­oid cancer, PDTC possesses a tendency for local invasion beyond the capsule of the thyroid, recurrence after surgical resection and metastatic
dissemination, and as such is associated with a worse prognosis. PDTC displays a degree of dif­ferentiation on histology which lies on the spec­trum between the well-preserved differentiation of WDTC and the anaplastic features of UTC. In PDTC, the characteristic follicular or papillary appearance of WDTC is not present, instead less differentiated growth patterns are observed. The classification of thyroid cancer as PDTC remains poorly defined. The most recent World Health Organization classification of thyroid tumors does not provide a criteria for categor­ization of PDTC, yet biologically there appears to be thyroid tumors that behave more aggressively than WDTC [1]. Until recently, there has not been agreement among pathologists in the clas­sification of PDTC. A recently published diag­nostic criteria for PDTC based on tumor histol­ogy has been proposed after review of 83 cases at a consensus meeting of thyroid pathologists in Turin, Italy [2]. In this classification, variants of follicular and papillary thyroid cancer which dis­play more aggressive behaviors such as the columnar cell, tall cell, solid, and diffuse-scleros­ing variants of papillary thyroid cancer are not considered PDTC [3]. PDTC is characterized by (1) the presence of an insular, solid, or trabecular patternofgrowthonhistology,(2)theabsenceof nuclear features of papillary carcinoma, and (3) the presence of one or more of the following features: convoluted nuclei, three or more mitoses per 10 high-power fields or foci of tumor necrosis [2]. PDTC with a predominantly
J.G.H. Hubbard et al. (eds.), Endocrine Surgery, Springer Specialist Surgery Series, DOI 10.1007/978-1-84628-881-4_9, Ó Springer-Verlag London Limited 2009
121
122
ENDOCRINE SURGERY
insular growth pattern on histology has been referred to as insular carcinoma and represents a distinct variant of thyroid carcinoma which cannot be clearly related to follicular or papillary carcinoma, with an aggressive behavior and prog­nosis which lie between those of WDTC and ana­plastic cancers [4].
Insular Carcinoma
Insular carcinoma is an aggressive form of thyr­oid malignancy and accounts for 3–6% of cases of thyroid carcinoma [5–7]. It occurs more com­monly in females with a female to male ratio of 2:1 [4, 6, 8]. The meanage ofonset is 51–57 years, with a range from 11 to 79 [4, 6–8]. Most patients with insular carcinoma present with symptoms of an enlarging mass, with 8% presenting with symptoms related to metastatic disease [4, 7]. In 27–60% of cases, the tumor develops within a preexisting goiter [6, 7]. Insular carcinomas have generally reached a large size by the time of presentation, with a mean of 5–6 cm [6, 8, 9]. Extrathyroidal invasion of the cancer into adja­cent soft tissues and anatomical structures occurs in 69% at the time of presentation, includ­ing the trachea or larynx in 15% of cases [10]. Spread to regionallymph nodes may be apparent in 20–44% of patients at presentation and distant metastases in 8–67% [4, 9–11]. Distant metastatic spread occurs in 32–85% of patients, most fre­quentlyto the lung (61%) orbony skeleton (50%) and less commonly to the liver (11%) [4, 7–11].
Fine needle aspirates from insular lesions are diagnostic in most cases, with features typi­cal of high-grade follicular neoplasms [12]. Aspirates are generally hypercellular with minimal colloid, and cytopathology character­istically demonstrates numerous round to oval pleomorphic follicular cells with scant eosino­philic cytoplasm and uniform nuclei, arranged in small nests or as individual cells [12–14].
Insular carcinomas are solid tumors with a pale coloration, and regions of hemorrhage and necrosis within the tumor substance are com­monly present. The histological appearance of these tumors was first characterized by Carcan­giu, who described tumor cells forming large, well-defined nests, separated from surrounding tissue by prominent clefts [4]. Tumor cells are uniform, small, and rounded in appearance with a scant eosinophilic granular cytoplasm (Fig. 9.1) [9]. In contrast to UTC, cells display minimal
a
b
Fig. 9.1. (A) Photomicrograph of poorly differentiated thyroid
cancer with an insular growth pattern. Insulae contain relatively uniform cuboidal cells with scant eosinophilic cytoplasm and minimal pleomorphism. Nuclear features of papillary thyroid cancer are absent. (20magnification). (B) Poorly differentiated thyroid cancer with solid and trabecular growth patterns. A mitotic figure is present (arrow)(20 magnification).
pleomorphism, and tumor giant cells and multi­nucleatedcells are not identified. The tumor cells have nuclei which can appear optically clear and resemble those of papillary cancer, but nuclear overlapping and other features of papillary can­cer are not present. Cells can be arranged in characteristic nests, in solid sheets of cells or in a trabecular pattern, and can form small follicles [4, 6, 9, 15]. The tumors can display a predomi­nantly insular growth pattern or can contain mostly trabecular or solid arrangements [9, 16]. Mitoses are identified frequently throughout the tumor and occur to a variable extent. Areas of necrosis are commonly present and invasion of vascular structures is seen in 44–100% of
123
POORLY DIFFERENTIATED AND UNDIFFERENTIATED THYROID CANCER
tumours [4, 6, 9, 15]. Immunohistochemistry is useful in the characterization of these tumors. Staining for thyroglobulin is positive in almost all cases confirming the follicular cell origin of the tumors [4, 9, 15]. Stains for keratin are posi­tive in 75% of cases, and negative staining for calcitonin enables differentiation of these tumors from medullary thyroid carcinoma.
Pathogenesis of Poorly Differentiated Thyroid Cancer
Regions of WDTC are present in the resection specimens of insular carcinoma and other PDTC in 59% of cases, and PDTC can be found in association with 13% of UTC, suggesting that PDTC represents a step in the progression and transformation from WDTC to UTC. Genetic studies of WDTC, PDTC, and UTC using com­parative genomic hybridization have shown a progressive accumulation of chromosomal abnormalities from differentiated to undifferen­tiated forms [17]. Tissue microarray identifica­tion of four candidate gene mutations found a similar progressive increase in mutations occurring among WDTC, PDTC, and UTC pro­viding further evidence that PDTC may repre­sent an intermediate stage in dedifferentiation [18]. The tumor suppressor gene p53 may be involved in this process, as mutations are pre­sent in 32% of UTC and 12% of PDTC and rarely occur in WDTC [18].
Management and Outcomes of Poorly Differentiated Thyroid Cancers
PDTC is uncommon in comparison to WDTC, and fewer studies exist which examine the role of surgical and adjuvant treatments of this dis­ease. In contrast to WDTC, multimodality treat­ment with a combination of aggressive surgical resection or debulking, radioactive iodine, and external beam radiotherapy may be indicated to achieve local control of the tumor [3]. In the initial description of insular PDTC from a series of 25 patients at the University of Florence, surgical resection was performed in 24 cases of which 20 were total or near-total thyroidec­tomies. This was combined with formal lymph node dissection in seven cases, and external
beam radiotherapy was given postoperatively in two cases. The mortality during the 8-year period of follow up of these patients was 56%, with 84% of cases developing locoregional recurrence or disseminated disease. Recurrent disease in the neck developed in 50% of patients who under­went thyroid lobectomy and in 42% of those who underwent total thyroidectomy. Surgical resec­tion by total or near-total thyroidectomy was performed for 20 of 22 patients managed at the Queen Mary Hospital in Hong Kong, and this was combined with postoperative external beam radiotherapy in eight cases [7]. Forty-two per­cent of patients survived greater than 10 years, with disseminated metastatic disease developing in 32%. Postoperative radiotherapy to improve locoregional control has been recommended for PDTC due to the high incidence of extrathyroidal invasion, regional lymph node involvement, and locoregional recurrence, particularlywhen resec­tion has been macroscopically incomplete [3]. The actual benefit of external beam radiotherapy in this setting is not known. In a study which collectively reviewed the outcomes after treat­ment of previously published case series of insu­lar PDTC, external beam radiotherapy was not associated with an improvement in survival [8]. Given the high rate of local recurrence of PDTC, however, it is reasonable to recommend post­operative external beam radiotherapy to maxi­mize the chance of maintaining locoregional control.
In contrast to UTC, which is rarely capable of organifying iodine, uptake of shown in more than 80% of PDTC and can be effective in the treatment of local and dissemi­nated disease [9, 19]. Although the response to treatment of PDTC is poor compared to that of WDTC, [6, 10] and treatment with radioactive iodine was not associated with a survival advan­tage in two studies examining its role, should be given to all patients with PDTC post­operatively because of the potential benefit and lack of morbidity associated with this treatment [3, 6, 8, 10]. In patients with tumors capable of taking up iodine, whole-body scanning with radioactive iodine can detect distant metastases. Positron emission tomography with F18-fluor­odeoxyglucose in patients with PDTC shows uptake of the isotope in most cases and has been used in the assessment of metastatic dis­ease where tumor does not take up radioactive iodine [20, 21].
131
I has been
131
I
124
ENDOCRINE SURGERY
In a large study of 183 cases of PDTC demon­strating an insular histology from the University of Turin, a 5-year survival rate of 85% and 10-year survival of 67% was found [6]. Patients greater than 45 years, the presence of necrosis within the tumor, and higher numbers of mitoses on histology were associated with a worse prognosis. In the review combining the results of previously published series of insular PDTC, a 5-year survival of 72% and 10-year survival of 52% were calculated [8]. Patients older than 45 years and the presence of disse­minated disease were associated with a higher mortality in this study. Although supported by level IV evidence only, aggressive surgical resec­tion followed by therapy for locoregional control appears to offer the best chance of long-term survival for patients with PDTC [3]. Systemic therapy should also be considered within a study proto­col because of the high likelihood of developing disseminated metastatic disease.
131
I and external beam radio-
Undifferentiated (Anaplastic) Thyroid Cancer
Undifferentiated (anaplastic) thyroid carci­noma is one of the most aggressive forms of cancer seen in humans and fortunately repre­sents only a small proportion of malignancies of the thyroid gland. In sharp contrast to differen­tiated forms of thyroid cancer, anaplastic cancer is characterized by aggressive local invasion and early widespread metastatic dissemination, with few patients surviving longer than 12 months after presentation [22]. Local treatment with surgical resection and external beam radiother­apy and single modality systemic chemotherapy have limited roles in the management of UTC in achieving palliation and prolonging survival. The rarity of this disease has made it difficult to study.
Clinical Features
UTC is an uncommon form of thyroid malig­nancy, accounting for only 1.7% of all thyroid cancers recorded in the National Cancer Data­base of the American Cancer Society [23]. Stu­dies from the large Surveillance, Epidemiology and End Results Program (SEER) cancer
registry database of the National Cancer Insti­tute showed no change in the incidence of UTC from 1973–2002 [24]. UTC occurs most com­monly in the elderly, with a peak incidence seen in the seventh decade of life and a mean age of presentation between 65 and 75 years [22, 25–28]. It is rarely seen in patients younger than 40 years, and the mean age at presentation is considerably higher than that seen in differ­entiated thyroid cancers. Females are overre­presented in most series of UTC, with reported female to male ratios of 1.5:1 to 2:1 [22, 25–28]. Few risk factors have been associated with UTC. A higher incidence in iodine-deficient areas and regions of endemic goiter has been found in some studies but not in others [29–31]. A his­tory of irradiation of the head and neck may be seen in up to 10% of patients and a causal relationship has been suggested [27, 32–37]. UTC occurring following radiation exposures tend to occur at a younger age than is normally observed, and has a mean latency period of 27 years postexposure [34].
Most patients with UTC present with symp­toms related to a rapidly enlarging neck mass, accounting for 70–99% of presentations [22, 27, 28, 37–39]. In 10–29% of patients, enlargement of a previously stable goiter is the presenting feature [27, 37, 38, 40, 41]. A smaller proportion of patients may present with symptoms related to distant metastases (3–10%) or with systemic features such as weight loss [22, 27]. Symptoms had been present for a mean duration of 1 month prior to presentation in some studies [28, 38]. The size of the mass and its rapid growth are frequently associated with symp­toms of compression of the airway, upper aero­digestive tract or vascular structures with stridor, difficulty in breathing, dysphagia, evi­dence of superior vena cava obstruction or voice change noted in up to 51% of patients at presentation [27, 28, 37, 38]. Voice change when present may be due to the effects of local com­pression or to involvement of the recurrent laryngeal nerve by direct tumor invasion. Acute upper airway compromise may be the mode of presentation in 18% of cases [38].
Few patients with UTC present at an early stage of disease, and in most cases this is where small foci of UTC is discovered within a larger differentiated thyroid cancer or found inciden­tally at thyroidectomy performed for alternate indications [28, 41, 42]. Only 8% of patients with
125
POORLY DIFFERENTIATED AND UNDIFFERENTIATED THYROID CANCER
anaplastic carcinoma in the SEER database had disease confined to the thyroid gland at presen­tation [25]. Local invasion beyond the thyroid capsule is seen in greater than 82% of cases, involving surrounding structures including overlying strap muscles, the trachea and larynx, esophagus, common carotid artery, adjacent nerves, great vessels of the superior mediasti­num, and overlying skin [22, 37–39, 41]. A study of adjacent structures involved by UTC found recurrent laryngeal nerve involvement in 59%, trachea or larynx in 50%, esophagus in 23%, carotid artery in 16%, and skin in 7% [39]. Direct invasion ofstructures within the superior mediastinum can produce superior vena cava syndrome in a small number of cases (Fig. 9.2) [28, 37, 40]. Metastatic involvement of regional lymph nodes can be documented in 21–38% of patients at presentation and is seen in 83% of cases at autopsy [25, 37, 38]. Hematogenous dissemination of the tumor to distant sites can be demonstrated in 43–64% of patients at the time of initial assessment and is present in 87% of cases at autopsy [22, 25, 27, 28, 38, 43, 44]. The most common site of metastatic spread is to the lungs, seen in 75–88% of patients with meta­static disease [27, 28, 37, 44]. Less common sites
of metastases include the boney skeleton, brain, adrenal glands, and nonregional lymph nodes [22, 27, 28, 37, 43, 44].
A staging system for UTC was developed by Aldinger at the MD Anderson Cancer Center in a study of 84 patients [40]. In this study, it was found that patients with UTC confined to the thyroid (stage I) had a favorable prognosis in comparison to patients with extracapsular inva­sion or metastatic spread. The majority of patients with UTC fall into stages III and IV at presenta­tion. Within the TNM classification of thyroid cancers of the American Joint Committee on Can­cer, all anaplastic thyroid cancers are designated as T4, stage IV disease due to the poor prognosis of patients with this malignancy [45].
Pathology
UTC present as large, bulky masses arising from the thyroid gland. Macroscopically, these tumors have a pale, white, or tan appearance on sectioning and are firm or hard on palpation (Fig. 9.3) [46–48]. Areas of hemorrhage, necro­sis, and cystic degeneration within the tumor substance are frequently apparent and the tumor may also contain regions of calcification [46, 48]. The tumor commonly displays indis­tinct margins with invasion into the adjacent residual thyroid parenchyma, which may
Fig. 9.2. Computed tomography of the thorax of a patient
with undifferentiated thyroid cancer presenting with superior vena cava syndrome. Invasion and tumor extension within the right brachiocephalic vein and superior vena cava toward the right atrium is demonstrated (large arrow). A pulmonary metastasis is also present (small arrow).
Fig. 9.3. Postresection specimen showing replacement of the
left lobe of the thyroid by undifferentiated thyroid cancer. The specimen has been sectioned to demonstrate a bulky pale tumor mass infiltrating the substance of the thyroid gland with areas of necrosis and hemorrhage. The mass was resected in continuity with the overlying strap muscles which were invaded by the tumor (seen to the left of the specimen).
126
ENDOCRINE SURGERY
appear normal or contain evidence of preexist­ing nodular disease [47]. Extracapsular invasion of the tumor into surrounding structures in also commonly observed.
The histological appearance of UTC varies considerably among cases, and criteria for his­tological diagnosis have been defined by the World Health Organization [1, 49]. Three histo­logical patterns are commonly identified: giant cell, spindle cell, and squamoid cell types (Fig. 9.4) [46–48]. In the giant cell form, large rounded neoplastic cells are seen with abundant eosinophilic cytoplasm, which display bizarre arrangements of hyperchromatic nuclei or be multinucleated. In the cases where spindle cells predominate, elongated fusiform cells with hyperchromatic nuclei form fascicles, often with a dense collagenous stroma, and the appearance can resemble that of sarcoma. Squa­moid cellular patterns are seen less commonly than giant and spindle cell forms, and display flattened cells with abundant eosinophilic cyto­plasm that form tumor nests and islands that resemble squamous carcinoma. It is rare for one pattern to predominate within a tumor, with most cases of UTC containing regions of varying histological appearance. In all forms, tumor cells have a high mitotic rate and fre­quent mitoses are demonstrated within sec­tions. Large multinucleated cells resembling osteoclasts may also be seen scattered in some tumors [47]. Areas of necrosis and hemorrhage within the tumor substance are common, and there is frequently an inflamma­tory cell infiltrate within the stroma. In all cases, UTC displays a distinct propensity for metastasis, with areas of invasion into vascular structures and lymphatic channels routinely identified in specimens. Histological variants of UTC have also been described and display similarly aggressive tumor behavior and poor prognosis. In the paucicellular variant of spin­dle cell UTC, prominent fibrosis is seen with few atypical spindle-shaped cells seen within a dense collagenous stroma with scattered inflammatory cells [47, 50]. This lack of cellu­larity makes diagnosis by fine needle aspiration (FNA) difficult, and the histological appearance can closely resemble Riedel’s thyroiditis [50]. An angiomatoid variant of UTC has also been reported and occurs very rarely, with histolo­gical features similar to angiosarcoma but with
a
b
c
Fig. 9.4. (A) Photomicrograph of undifferentiated thyroid
cancer of giant cell type. Large poorly cohesive cells with pleomorphic nuclei are seen in a haphazard arrangement. Areas of hemorrhage and necrosis are prominent. Mitotic figures and multinucleated giant cells are shown (arrow) (20magnification). (B) Undifferentiated thyroid cancer with spindle cell growth pattern. Elongated fusiform cells are haphazardly arranged in fascicles with a collagenous stroma. Cells demonstrate hyperchromatic pleomorphic nuclei (20magnification). (C) Undifferentiated thyroid cancer with invasion into adjacent strap muscle (arrows) (20 magnification).
127
POORLY DIFFERENTIATED AND UNDIFFERENTIATED THYROID CANCER
immunohistochemical staining consistent with a thyroid follicular cell origin [51].
UTC can closely resemble lymphoma, poorly differentiated medullary carcinoma, sarcoma, and some metastatic lesions to the thyroid both clinically and in histologic appearance. These malignancies must be differentiated from UTC as their treatment and prognosis are very differ­ent. Primary lymphoma of the thyroid shows a complete response to external beam radiother­apy in 88% of cases, and combined modality treatment with radiotherapy and chemotherapy has resulted in 5-year survival rates of 70% [52–54]. Medullary thyroid cancer also has a more favorable prognosis than UTC, with over­all 5-year survival rates of 68–86% [23]. As medullary thyroid cancer can be a manifestation of the familial syndromes of multiple endocrine neoplasia (MEN) type 2A and 2B or familial non­MEN medullary thyroid cancer, its differentia­tion from UTC may be important in the genetic counseling of siblings and offspring.
Immunohistochemistry is a useful adjunct to histology in this regard and shows a characteristic staining pattern. UTC contains few if any cells that stain positively for thyroglobulin unlike more differentiated forms of thyroid cancer. Stains for keratin and vimentin are positive in up to 80 and 93% of cases, respectively, and con­firm an epithelial origin of the tumor [27, 55]. The absence of staining for calcitonin and chromogra­nin differentiate UTC from medullary thyroid cancer, and the absence of leukocyte markers differentiates UTC from lymphoma [56].
Histological examination of the remnant thyroid tissue adjacent to the tumor reveals associated pathology in many cases. Benign multinodular disease can be identified in the adjacent thyroid remnant in 20% of resected specimens [22]. UTC can be seen in close asso­ciation with a focus of differentiated papillary or follicular carcinoma in 23–89% of cases, and these lesions are more frequently papillary than follicular in nature [7, 22, 27, 37, 40, 43, 57–59]. The presence of such lesions in close proximity to UTC lends support to the sugges­tion that many cases of UTC arise by anaplastic transformation from preexisting foci of differ­entiated thyroid cancer [60]. Further evidence for this lies in the fact that 16–21% of patients with UTC have a prior history of differentiated thyroid cancer [27, 28, 40, 41]. Studies of the genetic material of anaplastic cancer cells and
those of the associated differentiated carcinoma show similarities in aneuploidy, candidate gene mutations and chromosomal losses and band­ing patterns that suggest that transformation has occurred [61–64]. Anaplastic transforma­tion of WDTC to UTC is of clinical importance as it supports an aggressive approach to the surgical resection of thyroid lesions suspicious for malignancy in an attempt to reduce the risk of developing an aggressive cancer within a pre­existing low-risk lesion.
The molecular genetics of UTC has been stu­died to further define the pathogenesis of these cancers. Somatic mutations of the tumor sup­pressor gene p53 are seen in 32–88% of UTC and yet are uncommon in differentiated thyroid cancer, and this may play a role in the transfor­mation of these tumors as a late step in their dedifferentiation [18, 38, 65–70] Mutations of BRAF, RAS, overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1); bcl-2 and Nm23 genes have also been demonstrated in UTC [18, 61, 67, 71–73]. Expression of B-catenin and E-cadherin, transmembrane glycoproteins involved in inter­cellular adhesion, is decreased in UTC compared to differentiated cancers [74]. Chromosomal abnormalities are seen with increasing frequency in the progression from differentiated to UTCs, and tissue microarray analysis of a panel of seven genes involved in cell growth signaling showed that a number of genetic mutations are involved in this process [17, 18, 75]. It is likely that a number of sequential gene mutationsand genetic events are involved in the pathogenesis of UTC.
Assessment and Evaluation
The presence of a rapidly enlarging neck mass arising from the thyroid confirmed on physical examination should suggest the possibility of UTC, particularly in the elderly. The diagnosis in most cases can be made on FNA biopsy of the neck mass. Careful examination of aspirates by an experienced cytologist can correctly diag­nose UTC in 84–90% of cases [76]. The finding of tumor giant cells, marked cellular pleo­morphism and atypia, frequent mitoses, and spindle-shaped cells is characteristic [48, 76, 77]. The accuracy of FNA can be limited by the presence of extensive tumor fibrosis, necrosis or hemorrhage, hypocellularity of malignant cells, marked leukocyte infiltration, and the presence
128
ENDOCRINE SURGERY
of differing degrees of differentiation within the lesion [76]. Formal surgical biopsy of the thyr­oid is occasionally required where FNA is not diagnostic.
Imaging has an important role in the evalua­tion of patients with UTC. Cross-sectional ima­ging of the neck and mediastinum using computed tomography (CT) can correctly define the extent of invasion into adjacent struc­tures such as the trachea, esophagus, and car­otid sheath in a high proportion of cases, and can assess the extent to which invasion or exten­sion of the tumor into the superior mediasti­num and its contents has occurred (Fig. 9.5)
a
[78]. UTC are seen as large masses arising from the thyroid, with low attenuation and poorly defined margins on CT. Areas of dense calcification and necrosis are commonly seen within the tumor mass [78]. Magnetic resonance imaging has also been used in the assessment of local invasion with similar accuracy [79]. Cor­rectly defining the extent of extrathyroidal inva­sion in the neck is invaluable in the preoperative assessment of the surgical resectability of the tumor [78]. Imaging of the chest by CT or plain radiographs should also be performed as a staging investigation, as patients with meta­static disease will have pulmonary lesions in more than 85% of cases (Fig. 9.6) [27, 44]. Posi­tron emission tomography using 18-Fluoro­deoxyglucose has also been used to assess the presence and extent of disseminated metastatic disease, and should be considered in the evalua­tion of UTC [80].
Fiber-optic examination of the larynx and upper airway should be performed to assess vocal cord function and to look for the presence of external invasion of the airway by tumor. Indirect laryngoscopy reveals vocal cord paresis consistent with involvement of the recurrent laryngeal nerve in 25% of cases [37, 38].
b
Fig. 9.5. (A) Cross-sectional computed tomography appear-
ance of undifferentiated thyroid cancer demonstrating a diffu­sely invasive large tumor mass arising within the right lobe of the thyroid compressing the airway. Extracapsular invasion involving the adjacent trachea and esophagus and enlarged cervical lymph nodes (arrow) are shown. (B) Coronal sections demonstrating tumor invasion into the right side of the tra­cheal wall (arrow) by undifferentiated thyroid cancer. A focus of calcification is seen within the tumor.
Fig. 9.6. Computed tomography of the thorax of a patient
with undifferentiated thyroid cancer demonstrating a 2.5-cm pulmonary metastasis posteriorly within the lower lobe of the left lung (arrow). A smaller metastasis within the posterior right lower lobe is also seen.
129
POORLY DIFFERENTIATED AND UNDIFFERENTIATED THYROID CANCER
Management Strategies
The therapeutic options available in the man­agement of UTC include surgical resection and external beam radiotherapy to remove or con­trol local disease within the neck, and systemic therapy with chemotherapy given to enhance the effect of radiotherapy and to control disse­minated metastatic disease. UTC presents at an advanced stage with aggressive local invasion or distal metastatic disease present in most patients, and curative resection is possible in only a small proportion [22]. In most cases, the aims of treatment are to control the effects of local tumor growth in the neck, to palliate symptoms of local and disseminated disease, and to improve the quality of life when possible. Modern strategies in managing these malignan­cies frequently employ a combination of treat­ment modalities to achieve these aims. Unlike differentiated forms of thyroid cancer, UTC does not take up radioactive iodine, and there­fore systemic therapy with this modality is of no clinical benefit. Treatment protocols frequently need to take into consideration the advanced age and poor performance status of many patients with this malignancy.
A review of the therapeutic options available in the management of UTC needs to take into account the different modes of presentation of this disease. UTC tends to present with compli­cations of local growth and invasion (including airway compromise), with complications of dis­seminated disease, or occasionally as an inci­dental finding at an early stage. The approach to management must be modified as dictated by the mode of presentation of the patient and the clinical findings after appropriate assessment and investigation.
Clinical Scenario 1: Incidental Finding of UTC
Patients with UTC confined to the thyroid gland represent only 8% of cases, and their prognosis is the most favorable with long-term survival possible after complete resection of the tumor [25]. Many of the cases in this subgroup repre­sent foci of UTC found within larger more differentiated thyroid cancers, or discovered incidentally within the resection specimen at thyroidectomy for another indication [42]. In
patients where UTC is found as a small focus without extrathyroidal invasion, a 1-year survi­val rate of 73% and a 2-year survival rate of 46% have been reported [59]. In this way, although the prognosis of patients with a small focus of UTC completely resected compares favorably to larger clinically apparent anaplastic cancers, additional treatment with external beam radio­therapy and chemotherapy have been recom­mended due to the risk of recurrent and disse­minated disease.
Much of the favorable prognosis associated with small and incidentally found UTC lies in their complete resection prior to progression of disease beyond the thyroid. The majority of patients with UTC unfortunately present with advanced disease where complete resection of the tumor with a curative intent is not possible [22, 27]. Complete surgical resection of UTC confined to the thyroid offers the greatest chance of long-term survival, and has been combined with postoperative chemoradiother­apy to achieve 5-year survival rates of 50–60% [37, 43]. A Japanese study of 11 patients with a small focus of UTC found incidentally, the mor­tality was 36% and in three patients death was due to complications of locoregional recurrence in the neck [42]. Adjuvant treatment with exter­nal beam radiotherapy has been recommended to reduce this risk [28, 42]. In a study of 67 patients with UTC from the Massachusetts Hos­pital, radiotherapy was given after surgical resection in all cases and was associated with an improvement in survival at higher doses (>45 Gy) [28]. Complete surgical resection was achieved in 18% of cases and was associated with a significantly higher survival than incom­pletely resected tumors, with 83% of these patients surviving beyond 3 years. Radiother­apy combined with surgical resection has been associated with an improved survival in patients studied in the SEER database [25]. Radiother­apy was, however, not associated with a reduced risk of local recurrence in a large study of 134 patients with UTC from the Mayo Clinic [22]. In this study, surgical resection was performed in 72% of cases, with complete resection achieved in 30%. Most patients received radiotherapy postoperatively. Patients treated surgically had a longer duration of survival than those mana­ged nonoperatively, but no improvement in sur­vival or local recurrence in the neck was seen after complete resection when compared with